New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
08:03 EDTAMPELuoxis obtains CE Marking for RedoxSYS diagnostic system
Ampio announced that its subsidiary Luoxis, an in vitro diagnostics company, has obtained CE Marking in Europe for its RedoxSYS Diagnostic System, the company's blood-based platform for assessing the level of oxidative stress in the body. This regulatory clearance allows Luoxis to engage in market development activities designed to establish the clinical utility of the RedoxSYS System in the critical care setting, and position the company for a successful launch in Europe, which is currently anticipated for 2015.
News For AMPE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 27, 2015
13:55 EDTAMPEAmpio mentioned cautiously by Seeking Alpha contributor
Reference Link
January 22, 2015
08:04 EDTAMPEAmpio subsidiary secures European distribution for RedoxSYS diagnostic system
Ampio subsidiary Luoxis Diagnostics has secured long-term agreements with European distributors Eurobio, Una Health Limited, and THP Medical, to offer Luoxis' RedoxSYS Diagnostic System to academic and pharma-based research centers within their respective territories. RedoxSYS is a diagnostic platform and robust research tool capable of measuring oxidation-reduction potential in the body in response to injury, illness, or stress. Eurobio was granted territorial rights to offer RedoxSYS to institutions based in France and Switzerland, while Una Health Limited and THP Medical were granted territorial rights to the U.K. and Austria, respectively. These are multi-year agreements with the option to renew at the 3-5 year mark.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use